ChronoScale Corporation Common Stock (NASDAQ:CHRN) Shares Gap Up - Still a Buy?

Key Points

• CHRN shares gapped higher, opening at $21.54 versus a prior close of $20.42 and last trading at $21.85 on volume of 12,585 shares.
• Analyst sentiment is mixed: Northland Securities initiated coverage with an “outperform” rating and a $32 price target, while the overall consensus remains “Hold” with a $19 target.
• The company reported a quarterly loss of $0.12 per share on $18.4 million in revenue, alongside a negative net margin of 135.66% and negative return on equity of 197.81%.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) gapped up prior to trading on Tuesday . The stock had previously closed at $20.42, but opened at $21.54. ChronoScale Corporation Common Stock shares last traded at $21.85, with a volume of 12,585 shares.

Analyst Ratings Changes

Several brokerages have issued reports on CHRN. Weiss Ratings upgraded shares of ChronoScale Corporation Common Stock from a "sell (d-)" rating to a "sell (d)" rating in a research report on Monday, August 24th. Northland Securities assumed coverage on ChronoScale Corporation Common Stock in a research note on Friday. They issued an "outperform" rating and a $32.00 price target on the stock. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $19.00.

ChronoScale Corporation Common Stock Price Performance

The business has a 50 day moving average of $21.52 and a 200 day moving average of $17.19. The company has a market cap of $3.11 billion, a PE ratio of -3.97 and a beta of 0.98. The company has a debt-to-equity ratio of 0.06, a current ratio of 0.51 and a quick ratio of 0.51.

ChronoScale Corporation Common Stock (NASDAQ:CHRN - Get Free Report) last issued its quarterly earnings data on Wednesday, August 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The company had revenue of $18.40 million for the quarter. As a group, research analysts predict that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Institutional Trading of ChronoScale Corporation Common Stock

A hedge fund recently raised its stake in ChronoScale Corporation Common Stock stock. Roble Belko & Company Inc lifted its position in ChronoScale Corporation Common Stock (NASDAQ:CHRN - Free Report) by 104.5% in the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,338 shares of the company's stock after acquiring an additional 1,195 shares during the period. Roble Belko & Company Inc owned 0.07% of ChronoScale Corporation Common Stock worth $25,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.42% of the company's stock.

About ChronoScale Corporation Common Stock

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets. The EksoWorks segment designs, engineers, manufactures, and markets exoskeleton devices to allow able-bodied users to perform difficult repetitive work for extended periods.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.